{"url_path":"/sec/adil/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-053907-index.html","accession_number":"0001213900-26-053907","cik":"0001513525","ticker":"ADIL","issuer_name":"ADIAL PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-053907-index.html","primary_entity_key":"0001513525","primary_entity_name":"ADIAL PHARMACEUTICALS, INC."},"word_count":521,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nThe exhibit index set forth below is incorporated\nby reference in response to this Item 6.\n\n \n\n3.1\n \n[Certificate of Incorporation of Adial Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1, File No. 333-220368, filed with the Securities and Exchange Commission on October 25, 2017).](http://www.sec.gov/Archives/edgar/data/1513525/000121390017010930/fs12017a2ex3-3_adial.htm)\n\n3.2\n \n[Amended and Restated Bylaws of Adial Pharmaceuticals, Inc., dated February 22, 2022 (Incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K, File No. 001-38323, filed with the Securities and Exchange Commission on March 28, 2022).](http://www.sec.gov/Archives/edgar/data/1513525/000121390022015562/f10k2021ex3-3_adialpharma.htm)\n\n3.3\n \n[Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, File No. 001-38323, filed with the Securities and Exchange Commission on August 4, 2023).](http://www.sec.gov/Archives/edgar/data/1513525/000121390023063213/ea182870ex3-1_adialpharm.htm)\n\n3.4\n \n[Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, File No. 001-38323, filed with the Securities and Exchange Commission on August 1, 2025).](https://www.sec.gov/Archives/edgar/data/1513525/000121390025070642/ea025136301ex3-1_adial.htm)\n\n3.5\n \n[Certificate of Amendment to Certificate of Incorporation of Adial Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, File No. 001-38323, filed with the Securities and Exchange Commission on February 4, 2026).](http://www.sec.gov/Archives/edgar/data/1513525/000121390026012274/ea027503301ex3-1_adial.htm)\n\n10.1#\n \n[Form of Restricted Stock Award Agreement under 2017 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K, File No. 001-38323, filed with the Securities and Exchange Commission on April 9, 2026)](http://www.sec.gov/Archives/edgar/data/1513525/000121390026042057/ea028577201ex10-1.htm)\n\n31.1*\n \n[Certification by principal executive officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea028876201ex31-1.htm)\n\n31.2*\n \n[Certification by principal financial officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ea028876201ex31-2.htm)\n\n32.1*\n \n[Certification by principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028876201ex32-1.htm)\n\n32.2*\n \n[Certification by principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ea028876201ex32-2.htm)\n\n101.INS*\n \nInline XBRL Instance Document\n\n101.SCH*\n \nInline XBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n \nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n \nInline XBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n \nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n \nCover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)\n\n \n\n*\nFiled herewith\n\n#\nManagement contract or compensatory plan or arrangement required to be identified pursuant to Item 15(a)(3) of this report.\n\n  \n\n21 \n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \nADIAL PHARMACEUTICALS, INC.\n\n \n \n\n \nBy:\n/s/ Cary J. Claiborne\n\n \nName: \nCary J. Claiborne\n\n \nTitle:\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)\n\n \n \n\n \nBy:\n/s/ Vinay Shah\n\n \nName:\nVinay Shah\n\n \nTitle:\nChief Financial Officer\n\n(Principal Financial Officer and\n\nPrincipal Accounting Officer)\n\n \n\nDated: May 8, 2026\n\n \n\n22"}